Hello, everyone, and how are you today? We are just fine, thank you, despite the gloomy clouds hovering over the Pharmalot campus. After all, the glass is half full, even if some believe it is just a stupid glass. In any event, we are forging ahead with plans to talk to interesting people and forage for fascinating items to hold your attention. On that note, we also welcome juicy tips and unredacted documents. Meanwhile, here are some tidbits. Have a grand day and do stay in touch …
Ireland’s Health Service Executive and Vertex Pharmaceuticals appear ready to resume talks about the price of the Orkambi cystic fibrosis drug, the Irish Times reports. The National Center for Pharmacoeconomics, the national watchdog agency, says that Orkambi is too expensive at the price demanded by Vertex, which is about $170,000 annually. Hundreds of people have protested outside government offices this week seeking access to the treatment.
About the Author Reprints
